Says R&D "remains number one priority." Says capital allocation strategy "clear and remains unchanged." Says "confident" in achieving 2025 Pharmaceutical business sales targets. Expects "above market growth" in Pharmaceutical in 2023. Says "pleased" with integration of Abiomed. Comments taken from Q1 earnings conference call.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on JNJ:
- Johnson & Johnson Earnings Report: Is it a Beat?
- JNJ Up as Q1 Results Beat Estimates, Raises Outlook
- Johnson & Johnson raises quarterly dividend 5.3% to $1.19 from $1.13 per share
- Genmab announces Q1 net sales of DARZALEX $2.26B
- Johnson & Johnson raises FY23 adjusted EPS to $10.60-$10.70 from $10.45-$10.65